% | $
Quotes you view appear here for quick access.

Regenerx Biopharmaceuticals Inc. Message Board

  • snogreen snogreen Jun 21, 2011 5:25 PM Flag

    The NIH deal

    The NIH owns this TB 4 issud patent, but I believe RGN has rights:

    <<RegeneRx Biopharmaceuticals, Inc. (Pink Sheets: RGRX), announced today that it has signed an exclusive licensing agreement with the National Institutes of Health (NIH) for Thymosin Beta 4 (Tß4) a compound which has shown exciting potential in the field of wound healing. For the past several years the NIH's Institute of Dental and Craniofacial Research (NIDCR) has been exploring the vital role of Tß4 in the regeneration, remodeling, and healing of wounds in animal models. According to a paper published in The Journal of Investigative Dermatology, entitled "Thymosin Beta 4 Accelerates Wound Healing," the authors conclude that, "These results suggest that Tß4 is a potent wound healing factor with multiple activities that may be useful in the clinic."

    According to Dr. Allan L. Goldstein, founder and Chairman of RegeneRx, "We are very pleased to have the opportunity to commercialize Tß4 for tissue repair and wound healing. Tß4 represents a unique class of therapeutics being developed to speed the healing of injured tissues, accelerate the growth of blood vessels and reduce inflammation. We believe it offers a unique approach to quicker and more complete healing in people with chronic pressure sores, as well as other clinical indications."

    Under the NIH license, RegeneRx received exclusive world-wide rights to Tß4 with certain milestone payments and royalties due upon commercial sales. In 1998, the NIH filed a world-wide patent application covering this and other areas of interest. The Company hopes to begin Phase I clinical trials during 2001 and is presently working with the NIH toward that goal. The Company and NIH have also met with the U.S. FDA for a pre-IND meeting related to initiation of human clinical trials.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From the 10-k

      In 2001, we entered into a license agreement with the NIH under which we received an exclusive worldwide license from the NIH for all claims within the scope of the NIH’s patent application, and any issued patents, covering the use of Tß4 as a tissue repair and regeneration factor.

0.375-0.007(-1.96%)Oct 9 3:29 PMEDT